Abbott Laboratories delivers with exceptional consistency — all four recent quarters within a fraction of a percent of consensus — and offers 18.3% headroom to the analyst price target with a roughly 4-to-1 favorable risk/reward; the principal headwinds are a confirmed price downtrend and an unusually extreme put/call ratio that warrants monitoring before adding exposure.
Thesis pillars
- Consistent Earnings Delivery Streak↓Deteriorating
- Confirmed Price Downtrend Below 200ma↓Deteriorating
- Extreme Put Call Ratio Hedge Demand↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Abbott Laboratories (ABT) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $108.33, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international sales (61.0%); Analyst target reached - limited upside remaining.
Abbott Laboratories develops, manufactures, and sells healthcare products across four segments: Established Pharmaceuticals (branded generics sold in emerging markets), Diagnostic Products, Nutritional Products, and Medical Devices including FreeStyle Libre CGM and MitraClip.... Read more
Hold if already holding. Not a fresh buy at $108.33, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international sales (61.0%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.1/10, moderate confidence.
Passes 5/9 gates (clean insider activity, news events none recent, earnings proximity 39d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.
Recent developments
updated 2026-09-05Recent Developments — Abbott Laboratories
Latest news
- NEWS Abbott (ABT) Stock May Be 32% Undervalued As Legal Overhang Fades - simplywall.st — simplywall.st positive
- NEWS Reasons to Retain Abbott Stock in Your Portfolio for Now - TradingView — TradingView positive
- NEWS Abbott Laboratories Q2 preview: Analysts see healthy growth backed by Exact Sciences acquisition - Seeking Alpha — Seeking Alpha positive
- NEWS Benchmark reiterates Buy on Abbott Labs stock ahead of Q2 results - Investing.com — Investing.com positive
- NEWS Abbott's Medical Device Strategy Supports Long-Term Growth Outlook - qz.com — qz.com positive
Generated 2026-09-05T21:12:03Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicinternational sales61%10-K Item 1A: 'Sales outside of the U.S. in 2025 made up approximately 61 percent of Abbott's net sales'
Material Events(8-K, last 90d)
- 2026-04-27Item 5.02LOWKevin Conroy named to Abbott Board of Directors on April 24, 2026. Shareholders also approved 2026 Incentive Stock Program at Annual Meeting, replacing the 2017 Program. Routine board appointment; no officer departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $108.33, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international sales (61.0%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $114.99 (+6.1%), stop $104.14 (−4.0%), A.R:R -0.0:1. Score 5.1/10, moderate confidence.
Take-profit target: $114.99 (-0.1% upside). Target $114.99 (+6.1%), stop $104.14 (−4.0%), A.R:R -0.0:1. Stop-loss: $104.14.
Concentration risk — Geographic: international sales (61.0%); Analyst target reached - limited upside remaining; Weak growth.
Abbott Laboratories trades at a P/E of 35.2 (forward 17.9). TrendMatrix value score: 4.7/10. Verdict: Hold.
33 analysts cover ABT with a consensus score of 4.1/5. Average price target: $120.
What does Abbott Laboratories do?Abbott Laboratories develops, manufactures, and sells healthcare products across four segments: Established...
Abbott Laboratories develops, manufactures, and sells healthcare products across four segments: Established Pharmaceuticals (branded generics sold in emerging markets), Diagnostic Products, Nutritional Products, and Medical Devices including FreeStyle Libre CGM and MitraClip. Approximately 61% of net sales came from outside the United States in 2025, with roughly 115,000 employees serving customers in more than 160 countries.